Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 5 | 2022 | 31 | 2.840 |
Why?
|
| CD4 Lymphocyte Count | 9 | 2020 | 656 | 1.620 |
Why?
|
| Laboratories | 5 | 2021 | 47 | 1.390 |
Why?
|
| Cryptococcus | 4 | 2018 | 10 | 1.330 |
Why?
|
| HIV Infections | 15 | 2024 | 5097 | 1.280 |
Why?
|
| Antigens, Fungal | 4 | 2018 | 9 | 0.940 |
Why?
|
| Prostate-Specific Antigen | 2 | 2022 | 10 | 0.900 |
Why?
|
| Mass Screening | 6 | 2020 | 245 | 0.900 |
Why?
|
| Rural Health Services | 2 | 2014 | 48 | 0.870 |
Why?
|
| Primary Health Care | 2 | 2023 | 240 | 0.860 |
Why?
|
| South Africa | 21 | 2024 | 7596 | 0.840 |
Why?
|
| Biopsy | 2 | 2020 | 38 | 0.840 |
Why?
|
| Cryptococcosis | 3 | 2018 | 17 | 0.790 |
Why?
|
| Health Expenditures | 1 | 2023 | 39 | 0.780 |
Why?
|
| Humans | 23 | 2024 | 14537 | 0.730 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 284 | 0.620 |
Why?
|
| Cost-Benefit Analysis | 3 | 2024 | 253 | 0.560 |
Why?
|
| Male | 12 | 2023 | 6754 | 0.560 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 1324 | 0.540 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2017 | 16 | 0.540 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 40 | 0.530 |
Why?
|
| Immunoassay | 1 | 2017 | 28 | 0.520 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 15 | 0.510 |
Why?
|
| Retrospective Studies | 4 | 2023 | 799 | 0.480 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 42 | 0.470 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2017 | 195 | 0.460 |
Why?
|
| Clinical Laboratory Services | 1 | 2014 | 4 | 0.450 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 91 | 0.430 |
Why?
|
| Health Care Costs | 1 | 2014 | 115 | 0.420 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2013 | 1 | 0.400 |
Why?
|
| Health Information Exchange | 1 | 2013 | 1 | 0.400 |
Why?
|
| Information Dissemination | 1 | 2013 | 7 | 0.400 |
Why?
|
| National Health Programs | 1 | 2013 | 78 | 0.370 |
Why?
|
| Communicable Disease Control | 2 | 2023 | 101 | 0.350 |
Why?
|
| Population Surveillance | 1 | 2013 | 325 | 0.350 |
Why?
|
| Age Distribution | 2 | 2021 | 107 | 0.350 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 468 | 0.320 |
Why?
|
| Adult | 8 | 2021 | 5913 | 0.310 |
Why?
|
| Aged | 4 | 2021 | 1740 | 0.310 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1422 | 0.300 |
Why?
|
| Middle Aged | 6 | 2021 | 3601 | 0.290 |
Why?
|
| Anti-Retroviral Agents | 3 | 2018 | 551 | 0.280 |
Why?
|
| Pilot Projects | 3 | 2019 | 179 | 0.280 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 280 | 0.230 |
Why?
|
| Data Mining | 2 | 2021 | 8 | 0.220 |
Why?
|
| Viremia | 1 | 2023 | 66 | 0.200 |
Why?
|
| Prevalence | 3 | 2021 | 1192 | 0.200 |
Why?
|
| Female | 6 | 2021 | 9103 | 0.180 |
Why?
|
| Tuberculosis | 2 | 2024 | 543 | 0.180 |
Why?
|
| Incidence | 2 | 2020 | 685 | 0.180 |
Why?
|
| Pandemics | 2 | 2021 | 296 | 0.180 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 109 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 139 | 0.180 |
Why?
|
| Sentinel Surveillance | 1 | 2021 | 115 | 0.170 |
Why?
|
| Unemployment | 1 | 2020 | 10 | 0.170 |
Why?
|
| Financing, Government | 1 | 2020 | 11 | 0.160 |
Why?
|
| Gender-Based Violence | 1 | 2020 | 12 | 0.160 |
Why?
|
| Young Adult | 3 | 2021 | 2498 | 0.160 |
Why?
|
| Viral Load | 1 | 2023 | 819 | 0.160 |
Why?
|
| Adolescent | 3 | 2021 | 2985 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 43 | 0.150 |
Why?
|
| Poverty | 1 | 2020 | 152 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| Infant | 2 | 2021 | 2244 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 64 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2019 | 321 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 239 | 0.140 |
Why?
|
| Developing Countries | 1 | 2020 | 400 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2021 | 1479 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2021 | 1748 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2017 | 40 | 0.130 |
Why?
|
| Pregnancy | 1 | 2022 | 1862 | 0.120 |
Why?
|
| Obesity | 1 | 2019 | 367 | 0.120 |
Why?
|
| Models, Biological | 1 | 2016 | 77 | 0.120 |
Why?
|
| Child | 1 | 2021 | 2242 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 385 | 0.120 |
Why?
|
| HIV | 1 | 2018 | 380 | 0.120 |
Why?
|
| Workload | 1 | 2014 | 13 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 199 | 0.110 |
Why?
|
| Point-of-Care Testing | 1 | 2014 | 71 | 0.110 |
Why?
|
| Hypertension | 1 | 2018 | 419 | 0.110 |
Why?
|
| Time Factors | 1 | 2014 | 507 | 0.100 |
Why?
|
| Medical Record Linkage | 1 | 2013 | 6 | 0.100 |
Why?
|
| HIV-1 | 2 | 2016 | 1260 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2019 | 472 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2019 | 1160 | 0.060 |
Why?
|
| Risk Factors | 2 | 2019 | 1475 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 34 | 0.060 |
Why?
|
| Probability | 1 | 2023 | 27 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 132 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2023 | 120 | 0.050 |
Why?
|
| Child Health Services | 1 | 2020 | 35 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
| Maternal Health Services | 1 | 2020 | 52 | 0.040 |
Why?
|
| Taxes | 1 | 2020 | 73 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 227 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 149 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 124 | 0.040 |
Why?
|
| Weight Gain | 1 | 2019 | 77 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2018 | 22 | 0.040 |
Why?
|
| Urban Population | 1 | 2020 | 257 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 253 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 967 | 0.030 |
Why?
|